Médecins Sans Frontières, Brussels, Belgium.
Galveston National Laboratory, University of Texas Medical Branch, Galveston.
J Infect Dis. 2023 Nov 13;228(Suppl 7):S474-S478. doi: 10.1093/infdis/jiad354.
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.
尽管现在已有针对埃博拉病毒病的批准治疗方法和疫苗,但即使患者接受新批准的疗法治疗,病死率仍高得令人无法接受。此外,这些对策预计对其他丝状病毒引起的疾病无效。在第十届国际丝状病毒研讨会上举行了一次主题专家会议,讨论应对这些空白的策略。提出了几种研究性治疗方法、疫苗候选物和联合策略。最大的挑战被确定为在丝状病毒病暴发期间实施安全和疗效的精心设计的临床试验。为此做好准备需要就旨在跨越所有高危国家的多次暴发的试验达成一致的共同方案。包括高危国家在内的跨国研究联盟将是就方案设计进行谈判和协调筹备工作的理想机制。讨论参与者建议在非洲举行后续会议,以建立这样一个联盟。